SavedAdd your journal

Journals / Retina-Vitreus / 2014 / Cilt: 22 - Sayı: 2

Sildenafil sitrat alan genç erkek bir hastada nonarteritik anterior iskemik optik nöropati

Nonarteritic anterior ıschemic optic neuropathy in a young male patient taking sildenafil citrate

Cemile ÜÇGÜL ATILGAN
Selam Yekta ŞENDÜL
Dilek GÜVEN
Pages
149–152
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The patient was evaluated clinically by angiography and optic coherence tomography.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Sildenafil (Viagra), Phosphodiesterase 5 (PDE-5) selective inhibitor and partial phosphodiesterase 6 (PDE-6) inhibitor is frequently prescribed for treatment of erectile dysfunction (ED).1 Instances of nonarteritic ischemic optic neuropathy (NAION) and permanent vision loss following ingestion of PDE-5 selective inhibitor have been reported.2-4 Sildenafil has been approved for the treatment of ED since 1998, and more than 150 million prescriptions have been writ- ten for more than 27 million men worldwide, many of whom are older, vasculopathic, and at risk for NAION.5 A few cases of NAION following PDE-5 selective inhibitor intake have been reported with no vasculopathy risk.5 Our case was a 35 year old male patient who has been taking this medicine for three years without prescription.
📊
Key Findings & Data:The only identifiable risk factor was small optic cup/optic disc ratio.
💡
Conclusion & Impact:The patient was evaluated clinically by angiography and optic coherence tomography.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Sildenafil (Viagra), Phosphodiesterase 5 (PDE-5) selective inhibitor and partial phosphodiesterase 6 (PDE-6) inhibitor is frequently prescribed for treatment of erectile dysfunction (ED).1 Instances of nonarteritic ischemic optic neuropathy (NAION) and permanent vision loss following ingestion of PDE-5 selective inhibitor have been reported.2-4 Sildenafil has been approved for the treatment of ED since 1998, and more than 150 million prescriptions have been writ- ten for more than 27 million men worldwide, many of whom are older, vasculopathic, and at risk for NAION.5 A few cases of NAION following PDE-5 selective inhibitor intake have been reported with no vasculopathy risk.5 Our case was a 35 year old male patient who has been taking this medicine for three years without prescription. The only identifiable risk factor was small optic cup/optic disc ratio. The patient was evaluated clinically by angiography and optic coherence tomography.

Özet

Fosfodiesteraz 5 (PDE-5) selektif inhibitörü ve parsiyel fosfodiesteraz 6 (PDE-6) inhibitörü olan Sildenafil (Viagra), erektil disfonksiyonun (ED) tedavisi için sıkça reçete edilmektedir.1 PDE-5 selektif inhibitör alımını takiben gelişen kalıcı viz- yon kaybı ve nonarteritik anterior iskemik optik nöropati (NAAİON) örnekleri daha önceleri rapor edilmiştir.2-4 Sildenafil 1998’de erektil disfonksiyon tedavisi için onayını almış ve tüm dünyada 27 milyondan fazla erkeğe 150 milyondan fazla re- çete edilmiştir. Bu hastaların çoğunluğu NAAİON için risk faktörleri taşıyan yaşlı ve vaskülopatik kişilerdir.5 Bir kaç olgu sunumunda PDE-5 selektif inhibitör alımını takiben NAAİON gelişen, vaskülopatik risk faktörleri olmayan erkek hastalar yayınlanmıştır. Bu hastalarda tanımlanabilir tek risk faktörünün küçük optik kap/optik disk oranı olduğu gösterilmiştir.5 Bizim olgumuz ise, üç yıldır reçetesiz bu ilacı kullanmakta olan 35 yaşında erkek bir hastaydı. Tek tanımlanabilir risk fak- törü ise küçük optik kap/optik disk oranıydı. Hasta optik koherens tomografi ve anjiografi ile klinik olarak değerlendirildi.

🔖

Cite This Article

ATILGAN, C. Ü., ŞENDÜL, S. Y., GÜVEN, D. (2014). Sildenafil sitrat alan genç erkek bir hastada nonarteritik anterior iskemik optik nöropati. Retina-Vitreus, Cilt: 22 - Sayı: 2, 149–152. https://ajindex.com/articles/305037

References (16)

  1. Burnett AL. Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health. J Androl 2008;29:3-14
  2. Pomeranz HD, Smith KH, Hart WM Jr et al. Sildenafil-asso- ciated nonarteritic anterior ischemic optic neuropathy. Oph- thalmology 2002;109:584-7
  3. Pomeranz HD, Bhavsar AR. Nonarteritic ischemic optic neu- ropathy developing soon after use of sildenafil (Viagra): a re- port of seven new cases. J Neuroophthalmol 2005;25:9-13
  4. Bollinger K, Lee MS. Recurrent visual field defect and isch- emic optic neuropathy associated with tadalafil rechallenge. Arch Ophthalmol 2005;123:400-1
  5. L Gorkin, K Hvidsten, RE Sobel et al. Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neu- ropathy. Int J Clin Pract 2006l;60:500-3
  6. Physicians Desk Reference, 55th ed. Montvale, NJ: Medical Economics, 2001. Viagra;2534-7
  7. Egan RA, Pomeranz HD. Sildenafil (Viagra) associated anterior ischemic optic neuropathy. Arch Ophthalmol 2000;118:291-2
  8. Hattenhauer MG, Leavitt JA, Hodge DO et al. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Oph- thalmol 1997;123:103-7
  9. Johnson LN, Arnold AC. Incidence of nonarteritic and arterit- ic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California. J Neuroophthalmol 1994;14:38-44
  10. Rucker JC, Biousse V, Newman NJ. Ischemic optic neuropa- thies. Curr Opin Neurol 2004;17:27-35
  11. Newman NJ, Scherer R, Langenberg P et al. The fellow eye in NAION: report from the ischemic optic neuropathy decompres- sion trial follow-up study. Am J Ophthalmol 2002;134:317-28
  12. Beck RW, Servais GE, Hayreh SS. Anterior ischemic optic neuropathy. IX. Cup-to-disc ratio and its role in pathogenesis. Ophthalmology 1987;94:1503-8
  13. Doro S, Lessell S. Cup-disc ratio and ischemic optic neuropa- thy. Arch Ophthalmol 1985;103:1143-4
  14. Burde RM. Optic disc risk factors for nonarteritic anterior isch- emic optic neuropathy. Am J Ophthalmol 1993;116:759-64
  15. The Ischemic Optic Neuropathy Decompression Trial Re- search Group. Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. Arch Ophthalmol 1996;114:1366-74
  16. Barbehenn E, Lurie P, Wolfe SM et al. Petition to the FDA to require a black box warning for erectile dysfunction drugs (VI- AGRA, CIALIS, LEVITRA) to warn of the potential for irre- versible vision loss (HRG Publicat